![Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - Normalized expression of TGF-b mRNA in WT, EV-, or FKBP51/FKBP5-stably transfected melanoma cells. WT sample expression 1/4 1. (n 1/4). Western blot assay of TGF-b levels in the same cells. Anti-Flag-labelled exogenous FKBP51/FKBP5. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FKBP51-FKBP5-Antibody-Western-Blot-NB100-68240-img0006.jpg "Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - Normalized expression of TGF-b mRNA in WT, EV-, or FKBP51/FKBP5-stably transfected melanoma cells. WT sample expression 1/4 1. (n 1/4). Western blot assay of TGF-b levels in the same cells. Anti-Flag-labelled exogenous FKBP51/FKBP5. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license.")
| Reactivity | Hu, PmSpecies Glossary |
| Applications | WB, ICC/IF, IHC, IP, KD |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 0.2 mg/ml |
| Immunogen | The immunogen recognized by this antibody maps to a region between residue 407 and 457 of human FK506 binding protein 5 (51 kDa FK506-binding protein) using the numbering given in entry NP_004108.1 (GeneID 2289). |
| Predicted Species | Primate (100%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | FKBP5 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Application Notes | Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections.Use in Immunocytochemistry/immunofluorescence reported in scientific literature (PMID:28978117). |
||
| Theoretical MW | 51 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||
| Control |
|
||
| Publications |
|
| Storage | Store at 4C. Do not freeze. |
| Buffer | TBS and 0.1% BSA |
| Preservative | 0.09% Sodium Azide |
| Concentration | 0.2 mg/ml |
| Purity | Immunogen affinity purified |
Secondary Antibodies |
Isotype Controls |
Research Areas for FKBP51/FKBP5 Antibody (NB100-68240)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Immunohistochemistry: FKBP51/FKBP5 Antibody [NB100-68240] - Sample: FFPE section of human prostate carcinoma. Antibody: Affinity purified rabbit anti-FKBP5/FKBP51 used at a dilution of 1:1,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/FKBP51-FKBP5-Antibody-Immunohistochemistry-NB100-68240-img0004.jpg "Immunohistochemistry: FKBP51/FKBP5 Antibody [NB100-68240] - Sample: FFPE section of human prostate carcinoma. Antibody: Affinity purified rabbit anti-FKBP5/FKBP51 used at a dilution of 1:1,000 (0.2ug/ml). Detection: DAB")
![Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - Western Blot and Immunoprecipitation: FKBP5/FKBP51 Antibody NB100-68240 - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 mcg) cells. NB100-68240 used for WB at 0.04 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 3 mcg/mg lysate. FKBP5/FKBP51 was also immunoprecipitated by rabbit anti-FKBP5/FKBP51 antibody NB100-68239, which recognizes an upstream epitope.](http://images.novusbio.com/fullsize/FKBP51-FKBP5-Antibody-Western-Blot-NB100-68240-img0002.jpg "Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - Western Blot and Immunoprecipitation: FKBP5/FKBP51 Antibody NB100-68240 - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 mcg) cells. NB100-68240 used for WB at 0.04 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 3 mcg/mg lysate. FKBP5/FKBP51 was also immunoprecipitated by rabbit anti-FKBP5/FKBP51 antibody NB100-68239, which recognizes an upstream epitope.")
![Knockdown Validated: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51/FKBP5 modulates EMT hallmarks. FKBP51/FKBP5 silencing of SAN melanoma cells decreases TGF-b and TbRIII expression. Normalized expression rates (mean +/-S.D.) of TGF-b mRNA levels; (n 1/4). FKBP51/FKBP5 siRNA-treated sample expression 1/4. 1. Western blot assay of TGF-b in SAN melanoma cells treated with nonsilencing (NS) RNA or FKBP51/FKBP5 siRNA. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license./4](http://images.novusbio.com/fullsize/FKBP51-FKBP5-Antibody-Knockdown-Validated-NB100-68240-img0005.jpg "Knockdown Validated: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51/FKBP5 modulates EMT hallmarks. FKBP51/FKBP5 silencing of SAN melanoma cells decreases TGF-b and TbRIII expression. Normalized expression rates (mean +/-S.D.) of TGF-b mRNA levels; (n 1/4). FKBP51/FKBP5 siRNA-treated sample expression 1/4. 1. Western blot assay of TGF-b in SAN melanoma cells treated with nonsilencing (NS) RNA or FKBP51/FKBP5 siRNA. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license./4")
![Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 increases expression of melanoma CSC markers. (a) FKBP51 silencing decreases ABCB5 levels. (Left) Normalized expression rates (arbitrary units (AU)) (mean±S.D.) of FKBP51 (black) & ABCB5 mRNA (grey) (n=3). FKBP51-treated sample expression=1. (Right) Western blot assay of ABCB5 & FKBP51 levels. (b) FKBP51 overexpression enhances ABCB5 levels. (Left) Normalized expression of FKBP51 mRNA (black) & ABCB5 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=3. (Left) Western blot assay of ABCB5 & FKBP51 levels in the same cells. Anti-Flag-labelled exogenous FKBP51. (c) ABCG2+ melanoma cells increase in FKBP51-overexpressing cells. (Upper) Normalized expression of FKBP51 mRNA (black) & ABCG2 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=5. (Lower) Flow cytometric histograms of ABCG2 expression (green population); mean±S.D. of counts are shown. (d) Enhanced FKBP51 mRNA levels in sorted ABCG2+ melanoma cells (SAN, upper; A375, lower). Whole cell expression=1; (n=3). (e) Enhanced EMT gene transcripts in sorted ABCG2+ melanoma cells. ABCG2− sample expression=1; n=3. (f) Expression of ABCG2 transcript in 9 deparaffinized tumours, 4 primary melanoma (M) samples, & 5 metastases (MM). A naevus sample was arbitrarily chosen with expression=1 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68240_rabbit-polyclonal-fkbp51-fkbp5-antibody-31020241612662.jpg "Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 increases expression of melanoma CSC markers. (a) FKBP51 silencing decreases ABCB5 levels. (Left) Normalized expression rates (arbitrary units (AU)) (mean±S.D.) of FKBP51 (black) & ABCB5 mRNA (grey) (n=3). FKBP51-treated sample expression=1. (Right) Western blot assay of ABCB5 & FKBP51 levels. (b) FKBP51 overexpression enhances ABCB5 levels. (Left) Normalized expression of FKBP51 mRNA (black) & ABCB5 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=3. (Left) Western blot assay of ABCB5 & FKBP51 levels in the same cells. Anti-Flag-labelled exogenous FKBP51. (c) ABCG2+ melanoma cells increase in FKBP51-overexpressing cells. (Upper) Normalized expression of FKBP51 mRNA (black) & ABCG2 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=5. (Lower) Flow cytometric histograms of ABCG2 expression (green population); mean±S.D. of counts are shown. (d) Enhanced FKBP51 mRNA levels in sorted ABCG2+ melanoma cells (SAN, upper; A375, lower). Whole cell expression=1; (n=3). (e) Enhanced EMT gene transcripts in sorted ABCG2+ melanoma cells. ABCG2− sample expression=1; n=3. (f) Expression of ABCG2 transcript in 9 deparaffinized tumours, 4 primary melanoma (M) samples, & 5 metastases (MM). A naevus sample was arbitrarily chosen with expression=1 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 increases expression of melanoma CSC markers. (a) FKBP51 silencing decreases ABCB5 levels. (Left) Normalized expression rates (arbitrary units (AU)) (mean±S.D.) of FKBP51 (black) & ABCB5 mRNA (grey) (n=3). FKBP51-treated sample expression=1. (Right) Western blot assay of ABCB5 & FKBP51 levels. (b) FKBP51 overexpression enhances ABCB5 levels. (Left) Normalized expression of FKBP51 mRNA (black) & ABCB5 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=3. (Left) Western blot assay of ABCB5 & FKBP51 levels in the same cells. Anti-Flag-labelled exogenous FKBP51. (c) ABCG2+ melanoma cells increase in FKBP51-overexpressing cells. (Upper) Normalized expression of FKBP51 mRNA (black) & ABCG2 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=5. (Lower) Flow cytometric histograms of ABCG2 expression (green population); mean±S.D. of counts are shown. (d) Enhanced FKBP51 mRNA levels in sorted ABCG2+ melanoma cells (SAN, upper; A375, lower). Whole cell expression=1; (n=3). (e) Enhanced EMT gene transcripts in sorted ABCG2+ melanoma cells. ABCG2− sample expression=1; n=3. (f) Expression of ABCG2 transcript in 9 deparaffinized tumours, 4 primary melanoma (M) samples, & 5 metastases (MM). A naevus sample was arbitrarily chosen with expression=1 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68240_rabbit-polyclonal-fkbp51-fkbp5-antibody-310202415535195.jpg "Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 increases expression of melanoma CSC markers. (a) FKBP51 silencing decreases ABCB5 levels. (Left) Normalized expression rates (arbitrary units (AU)) (mean±S.D.) of FKBP51 (black) & ABCB5 mRNA (grey) (n=3). FKBP51-treated sample expression=1. (Right) Western blot assay of ABCB5 & FKBP51 levels. (b) FKBP51 overexpression enhances ABCB5 levels. (Left) Normalized expression of FKBP51 mRNA (black) & ABCB5 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=3. (Left) Western blot assay of ABCB5 & FKBP51 levels in the same cells. Anti-Flag-labelled exogenous FKBP51. (c) ABCG2+ melanoma cells increase in FKBP51-overexpressing cells. (Upper) Normalized expression of FKBP51 mRNA (black) & ABCG2 mRNA (grey) measured in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1; n=5. (Lower) Flow cytometric histograms of ABCG2 expression (green population); mean±S.D. of counts are shown. (d) Enhanced FKBP51 mRNA levels in sorted ABCG2+ melanoma cells (SAN, upper; A375, lower). Whole cell expression=1; (n=3). (e) Enhanced EMT gene transcripts in sorted ABCG2+ melanoma cells. ABCG2− sample expression=1; n=3. (f) Expression of ABCG2 transcript in 9 deparaffinized tumours, 4 primary melanoma (M) samples, & 5 metastases (MM). A naevus sample was arbitrarily chosen with expression=1 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 interacts with the general transcriptional co-activator p300. (a, left) FKBP51 co-immunoprecipitates with p300. (a, right), p300 co-immunoprecipitates with FKBP51. Total-cell lysates were prepared by SAN melanoma cells transfected with FKBP51/Flag. Cell lysates were immunoprecipitated with anti-Kat3B/p300 (IP p300) or anti-Flag (IP FKBP51). Immunoprecipitated & total lysates were then subjected to western blot with anti-FKBP51 or anti-p300. (b) ChIP performed with SAN melanoma cells, silenced (FKBP51 siRNA) or not (NS RNA) for FKBP51. An enrichment of DNA (region at −3450 from TSS of ABCG2 gene) can be observed in p300-immunoprecipitated chromatin (NS RNA) compared with IgG sample. Such an enrichment appeared to be reduced when FKBP51 was silenced (FKBP51 siRNA) Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68240_rabbit-polyclonal-fkbp51-fkbp5-antibody-310202415532018.jpg "Western Blot: FKBP51/FKBP5 Antibody [NB100-68240] - FKBP51 interacts with the general transcriptional co-activator p300. (a, left) FKBP51 co-immunoprecipitates with p300. (a, right), p300 co-immunoprecipitates with FKBP51. Total-cell lysates were prepared by SAN melanoma cells transfected with FKBP51/Flag. Cell lysates were immunoprecipitated with anti-Kat3B/p300 (IP p300) or anti-Flag (IP FKBP51). Immunoprecipitated & total lysates were then subjected to western blot with anti-FKBP51 or anti-p300. (b) ChIP performed with SAN melanoma cells, silenced (FKBP51 siRNA) or not (NS RNA) for FKBP51. An enrichment of DNA (region at −3450 from TSS of ABCG2 gene) can be observed in p300-immunoprecipitated chromatin (NS RNA) compared with IgG sample. Such an enrichment appeared to be reduced when FKBP51 was silenced (FKBP51 siRNA) Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot JNK1 Antibody (228601) [Unconjugated]](https://images.novusbio.com/images2/JNK1_MAB17761_Western_Blot_5991.jpg)
![Western Blot JNK1 Antibody (228601) [Unconjugated]](https://images.novusbio.com/images2/JNK1_MAB17761_Western_Blot_6327.jpg)
![Immunocytochemistry JNK1 Antibody (228601) [Unconjugated]](https://images.novusbio.com/images2/JNK1_MAB17761_Immunocytochemistry__Immunofluorescence_20184.jpg)
![Western Blot ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Western_Blot_5097.jpg)
![Immunohistochemistry ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Immunohistochemistry_20696.jpg)
![Knockout Validated ERK2 Antibody [Unconjugated]](https://images.novusbio.com/images2/ERK2_AF1230_Knockout_Validated_22864.jpg)
![Western Blot c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Western_Blot_18923.jpg)
![Immunocytochemistry c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Immunocytochemistry__Immunofluorescence_18945.jpg)
![Simple Western c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Simple_Western_19175.jpg)
![Western Blot Pin1 Antibody (257417) [Unconjugated]](https://images.novusbio.com/images2/Pin1_MAB2294_Western_Blot_6024.jpg)
![Immunocytochemistry Pin1 Antibody (257417) [Unconjugated]](https://images.novusbio.com/images2/Pin1_MAB2294_Immunocytochemistry__Immunofluorescence_23049.jpg)
![Immunohistochemistry Pin1 Antibody (257417) [Unconjugated]](https://images.novusbio.com/images2/Pin1_MAB2294_Immunohistochemistry_7360.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")